Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof
(R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition.
1 . A method for improving cognition comprising administering to a subject (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof at a daily dose of less than 3 mg.
2 . The method of claim 1 wherein the daily dose is 1 mg or less.
3 . The method of claim 2 wherein the daily dose is 0.3 mg or less.
4 . (canceled)
5 . The method of claim 1 wherein the daily dose is 1 mg or less.
6 . The method of claim 5 wherein the daily dose is 0.3 mg or less.
7 . (canceled)
8 . The method of claim 1 wherein the daily dose is 1 mg or less.
9 . The method of claim 8 wherein the daily dose is 0.3 mg or less
10 . (canceled)
11 . The method of claim 1 wherein the daily dose is 1 mg or less.
12 . The method of claim 11 wherein the daily dose is 0.3 mg or less.
13 . (canceled)
14 . The method of claim 1 wherein the daily dose is 1 mg or less.
15 . The method of claim 14 wherein the daily dose is 0.3 mg or less.
16 . (canceled)
17 . The method of claim 1 wherein the daily dose is 1 mg or less.
18 . The method of claim 17 wherein the daily dose is 0.3 mg or less.
19 . (canceled)
20 . The method of claim 1 wherein the daily dose is 1 mg or less.
21 . The method of claim 20 wherein the daily dose is 0.3 mg or less.
22 . (canceled)
23 . The method of claim 1 wherein the daily dose is 1 mg or less.
24 . The method of claim 11 wherein the daily dose is 0.3 mg or less.
25 . The method of claim 1 , wherein the subject is suffering from anxiety or agitation.
26 - 28 . (canceled)